Tolmas Tolibovich Khamroev
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tolmas Tolibovich Khamroev has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Lola Lazizovna Akhunzhanova
Department of Clinical Laboratory diagnostics of Republican Specialized Scientific and Practical Medical Center of Pediatrics of the Ministry of Health of the Republic of Uzbekistan, Tashkent City, Uzbekistan
3 shared publications - Orifzhon Abdumalikovich Aripov
Department of Clinical Laboratory diagnostics of Republican Specialized Scientific and Practical Medical Center of Pediatrics of the Ministry of Health of the Republic of Uzbekistan, Tashkent City, Uzbekistan
3 shared publications - Abdumalik Nigmatovich Aripov
Department of Clinical Laboratory diagnostics of Republican Specialized Scientific and Practical Medical Center of Pediatrics of the Ministry of Health of the Republic of Uzbekistan, Tashkent City, Uzbekistan
2 shared publications - Abdusamad Utkirovich Nabiev
Department of Clinical Laboratory diagnostics of Republican Specialized Scientific and Practical Medical Center of Pediatrics of the Ministry of Health of the Republic of Uzbekistan, Tashkent City, Uzbekistan
2 shared publications - Abdumalik Nigmatovich Aripov
Department of Clinical Laboratory diagnostics of Republican Specialized Scientific and Practical Medical Center of Pediatrics of the Ministry of Health of the Republic of Uzbekistan, Tashkent City, Uzbekistan
1 shared publication - Burkhon Elmuradov
Institute of the Chemistry of Plant Substances, Uzbekistan Academy of Sciences, Mirzo Ulugbek Str. 77, Tashkent 100170, Uzbekistan
1 shared publication
Latest Publications
- Open Access
- 20 March 2026
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 1 (19) , 511-523
Determination of the Simultaneous Hepatoprotective and Antidepressant Activity of the Composition Hepalipin and Yantacin
Although only a few groups of drugs with hepatoprotective activity are recognized, the introduction of drugs with high liver protective activity, mainly based on natural compounds or plants, has become an urgent problem especially, over the last twenty years. A striking example of this is the fact that the hepatoprotective activity of existing phytotherapeutic drugs is not as high as that of synthetic drugs. However, secondary plant metabolites, including flavonoids, flavones, flavonols, and other naturally occurring biologically active compounds, are becoming a promising therapeutic alternative to traditional medicines in modern medicine. The priority purpose of this study is to introduce a new highly hepatoprotective and at the same time biologically active antidepressant of a new composition based on a combination of phospholipid, lycopene, glycerisic acid and yantacin obtained from plants. All of the research was done on rats, and the administration of heliothrin, a chemical that has a hepatotoxic effect, into the abdominal cavity in accordance with a rigorous plan resulted in significant chronic liver damage. Its hepatoprotector and antidepressant properties were compared to those of the well-known medication Phosphogliv and fluoxetine, which are both commonly used in medicine. The study's focus was a 1:1 mixture of heparin and yanatacin. As a result, the pharmacological composition that is being presented is completely safe, and research has shown that its constituents exhibit a markedly elevated activity not only in relation to the well-known medication phosphogliv, but also in relation to the ecdysteroid form of yantacin and hepalipin. Consequently, the pharmacological composition offered is entirely safe, and studies have demonstrated that its components have significantly higher activity not only when compared to the well-known drug phosphogliv, but also when compared to the ecdystenic form of yantacin and hepalipin.
- 20 March 2026
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 1 (19) , 511-523
Open AccessDetermination of the Simultaneous Hepatoprotective and Antidepressant Activity of the Composition Hepalipin and Yantacin
Although only a few groups of drugs with hepatoprotective activity are recognized, the introduction of drugs with high liver protective activity, mainly based on natural compounds or plants, has become an urgent problem especially, over the last twenty years. A striking example of this is the fact that the hepatoprotective activity of existing phytotherapeutic drugs is not as high as that of synthetic drugs. However, secondary plant metabolites, including flavonoids, flavones, flavonols, and other naturally occurring biologically active compounds, are becoming a promising therapeutic alternative to traditional medicines in modern medicine. The priority purpose of this study is to introduce a new highly hepatoprotective and at the same time biologically active antidepressant of a new composition based on a combination of phospholipid, lycopene, glycerisic acid and yantacin obtained from plants. All of the research was done on rats, and the administration of heliothrin, a chemical that has a hepatotoxic effect, into the abdominal cavity in accordance with a rigorous plan resulted in significant chronic liver damage. Its hepatoprotector and antidepressant properties were compared to those of the well-known medication Phosphogliv and fluoxetine, which are both commonly used in medicine. The study's focus was a 1:1 mixture of heparin and yanatacin. As a result, the pharmacological composition that is being presented is completely safe, and research has shown that its constituents exhibit a markedly elevated activity not only in relation to the well-known medication phosphogliv, but also in relation to the ecdysteroid form of yantacin and hepalipin. Consequently, the pharmacological composition offered is entirely safe, and studies have demonstrated that its components have significantly higher activity not only when compared to the well-known drug phosphogliv, but also when compared to the ecdystenic form of yantacin and hepalipin.
- Open Access
- 30 December 2024
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 17 (4) , 2739-2749
Evaluation of Antifibrotic Activity of a Combination of a New Phytocomposition and Proanthocyanidins in Rats.
Background: Today, chronic liver diseases and pathologies that develop as their complications, such as LC or HCC, cause various socio-economic as well as medical problems, and therefore the elimination of fibrosis processes in the liver is an important urgent problem. In the event of complications such as LC and HCC, the process of LF acts as an immediate bridge. Which, in turn, is responsible for stopping changes in the liver at the stage of fibrosis. Aim: The focus of the investigations was on how the composition under investigation affected the early stages of liver fibrosis. The antifibrotic action of the substance under investigation was assessed primarily by focusing on the invariance of lowered markers or a decrease in fibrosis rates. Experimental Approach: All the studies conducted were carried out on rats, while severe chronic liver damage was caused by the introduction into the abdominal cavity according to a strict scheme of heliothrin, a substance with a hepatotoxic effect. The object of the study was a combination of heparin and yanatacin 1:1, the antifibrotic activity of which was studied in comparison with the popular drug Phosphogliv, widely used in medical practice. Key Results: In the conducted studies, it was noted that the combination of heparin and yantacin normalizes disorders caused by heliotrin in experimental animals, in particular, enzyme activity, cytokine levels, bile secretion and liver index. According to this activity, the comparative drug showed a clear advantage over phosphogliv. Conclusion: The studies show that the studied combination only prevents the transition of the fibrous process to the second or third stage, and therefore the search for drugs that can completely eliminate the stage of fibrosis in the liver has not lost its relevance.
- 30 December 2024
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 17 (4) , 2739-2749
Open AccessEvaluation of Antifibrotic Activity of a Combination of a New Phytocomposition and Proanthocyanidins in Rats.
Background: Today, chronic liver diseases and pathologies that develop as their complications, such as LC or HCC, cause various socio-economic as well as medical problems, and therefore the elimination of fibrosis processes in the liver is an important urgent problem. In the event of complications such as LC and HCC, the process of LF acts as an immediate bridge. Which, in turn, is responsible for stopping changes in the liver at the stage of fibrosis. Aim: The focus of the investigations was on how the composition under investigation affected the early stages of liver fibrosis. The antifibrotic action of the substance under investigation was assessed primarily by focusing on the invariance of lowered markers or a decrease in fibrosis rates. Experimental Approach: All the studies conducted were carried out on rats, while severe chronic liver damage was caused by the introduction into the abdominal cavity according to a strict scheme of heliothrin, a substance with a hepatotoxic effect. The object of the study was a combination of heparin and yanatacin 1:1, the antifibrotic activity of which was studied in comparison with the popular drug Phosphogliv, widely used in medical practice. Key Results: In the conducted studies, it was noted that the combination of heparin and yantacin normalizes disorders caused by heliotrin in experimental animals, in particular, enzyme activity, cytokine levels, bile secretion and liver index. According to this activity, the comparative drug showed a clear advantage over phosphogliv. Conclusion: The studies show that the studied combination only prevents the transition of the fibrous process to the second or third stage, and therefore the search for drugs that can completely eliminate the stage of fibrosis in the liver has not lost its relevance.
- Open Access
- 31 December 2023
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 16 (4) , 2457-2467
Synthesis and Research Anticonvulsant Activity of Annulated Triazolo-Thiadiazine Derivative in Laboratory Animals
Epilepsy is a chronic non-communicable disease of the brain, which is estimated that five million people are diagnosed with epilepsy every year worldwide. In this regard the study studied the anticonvulsant properties of annulated 4-(6-phenyl-7H-[1,2,4] triazolo [3,4-b] [1,3,4] thiadiazin-3-yl)-aniline. Anticonvulsant activity was evaluated in various experimental models of convulsions in laboratory rodents. Oral dosages of 3, 10, 30, and 60 mg/kg of the study substances were given one hour prior to the experiment. Pentylenetetrazole (PTZ) convulsions were modeled using PTZ at a dose of 7 mg/kg subcutaneously, isoniazid convulsions were modeled using an oral dose of 300 mg/kg, and bicuculline convulsions were modeled using a subcutaneous dose of 2,7 mg/kg. Also, comparatively studied the antiepileptic activity of triazole derivatives with the well-known antiepileptic drug carbamazepine. In the conducted studies the studied compound showed carbamazepine-like activity at doses of 3 and 10 mg/kg in the model of seizures caused by strychnine, while at a dose of 30 mg/kg it showed high activity and in models induced using bicuculin and isoniazid, the studied drug showed activity similar to carbamazepine. On the contrary, the model of seizures induced by PTZ showed high activity at doses of 3, 10 and 30 mg/kg. The results obtained showed that triazole derivative had a pronounced antiepileptic activity, and further study can be proposed as a potential antiepileptic drug.
- 31 December 2023
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 16 (4) , 2457-2467
Open AccessSynthesis and Research Anticonvulsant Activity of Annulated Triazolo-Thiadiazine Derivative in Laboratory Animals
Epilepsy is a chronic non-communicable disease of the brain, which is estimated that five million people are diagnosed with epilepsy every year worldwide. In this regard the study studied the anticonvulsant properties of annulated 4-(6-phenyl-7H-[1,2,4] triazolo [3,4-b] [1,3,4] thiadiazin-3-yl)-aniline. Anticonvulsant activity was evaluated in various experimental models of convulsions in laboratory rodents. Oral dosages of 3, 10, 30, and 60 mg/kg of the study substances were given one hour prior to the experiment. Pentylenetetrazole (PTZ) convulsions were modeled using PTZ at a dose of 7 mg/kg subcutaneously, isoniazid convulsions were modeled using an oral dose of 300 mg/kg, and bicuculline convulsions were modeled using a subcutaneous dose of 2,7 mg/kg. Also, comparatively studied the antiepileptic activity of triazole derivatives with the well-known antiepileptic drug carbamazepine. In the conducted studies the studied compound showed carbamazepine-like activity at doses of 3 and 10 mg/kg in the model of seizures caused by strychnine, while at a dose of 30 mg/kg it showed high activity and in models induced using bicuculin and isoniazid, the studied drug showed activity similar to carbamazepine. On the contrary, the model of seizures induced by PTZ showed high activity at doses of 3, 10 and 30 mg/kg. The results obtained showed that triazole derivative had a pronounced antiepileptic activity, and further study can be proposed as a potential antiepileptic drug.
- Open Access
- 30 September 2023
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 16 (3) , 1815-1825
Antifibrotic Efficacy of a New Phytocomposition of Essential Phospholipids with Glycyrrhizic Acid, Ecdysterone, Lycopene and Proanthacyanidin in Experimental Severe Chronic Hepatitis Compared with Phosphogliv
Biomedical and Pharmacology Journal (BPJ) is an international, open access, peer reviewed, quarterly research journal.
- 30 September 2023
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 16 (3) , 1815-1825
Open AccessAntifibrotic Efficacy of a New Phytocomposition of Essential Phospholipids with Glycyrrhizic Acid, Ecdysterone, Lycopene and Proanthacyanidin in Experimental Severe Chronic Hepatitis Compared with Phosphogliv
Biomedical and Pharmacology Journal (BPJ) is an international, open access, peer reviewed, quarterly research journal.